BioSyent Inc.

2601 Matheson Boulevard E.
Suite 5
Mississauga
Ontario
L4W 5A8
Canada

Tel: 905-206-0013
Fax: 905-206-1413

Show jobs for this employer

67 articles with BioSyent Inc.

  • BioSyent Inc. released its financial results for the three and nine months ended September 30, 2021.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2021 on Thursday, November 18, 2021 at 5:00pm ET. A presentation on the Company’s third quarter and year-to-date 2021 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX ® Pd Powder 15 by its subsidiary, BioSyent Pharma Inc., in Canada.

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and six months ended June 30, 2021.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30, 2021 on Wednesday, August 25, 2021 at 8:00am ET.

  • BioSyent Inc. is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an agreement to license a unique technology application to support better treatment outcomes for patients with iron deficiencies in Canada and BioSyent’s international markets.

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months ended March 31, 2021. Key highlights include: Record first quarter (Q1) 2021 Net Revenues of $7,419,889 increased by 22% versus Q1 2020 Q1 2021 Canadian Pharmaceutical Net Revenues of $6,233,763 increased by 5% versus Q1 2020 Q1 2021 International Pharmaceutical Net Revenues of $1,140,279 increased by 1,578% versus Q1 2020 Q1 2021

  • BioSyent Inc. will be reporting its financial results for the three months ended March 31, 2021 on Thursday, May 27, 2021 at 8:00am EDT.

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference

  • BioSyent Inc. announces that its Board of Directors has approved a grant of 67,252 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan.

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2020.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2020 on Wednesday, March 17, 2021.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments of Combogesic ® to Canadian wholesalers. Combogesic ® is the first fixed-dose combination of acetaminophen and ibuprofen in a single tablet in Canada and is indicated for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Combining two

  • MISSISSAUGA, Ontario, Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the Company’s Notice of Intention to Make a Normal Course Issuer Bid (the “NCIB”). Pursuant to the NCIB, BioSyent may purchase up to 950,000 of its common shares (“Shares”) over a 12-month period, representing approximately 7.42% of the Shares outstanding as of December 11, 2020.   The NCIB will commence

  • BioSyent Inc. released its financial results for the three and nine months ended September 30, 2020.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended September 30, 2020 on Thursday, November 26, 2020. A presentation on the Company’s third quarter and year-to-date 2020 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange und

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the launch of FeraMAX® Pd Therapeutic 150, the first new product incorporating FeraMAX® Pd, a new oral iron supplement delivery system, by its subsidiary BioSyent Pharma Inc. in Canada.

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been included in the 32nd annual Growth List, the definitive ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s.

  • BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the introduction of FeraMAX ® Pd, a new oral iron supplement formulation, by its subsidiary BioSyent Pharma Inc. FeraMAX ® Pd is a patented delivery system for the treatment of iron deficiency anemia and will be the foundation of future product developments. BioSyent Pharma has a deep expertise and experience in the iron deficiency anemia therapy and pre

  • BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive License and Supply Agreement with a European partner for a new product in the women’s health market for Canada. The product has been approved for sale in Canada, the U.S.A., Europe and in several other markets around the world.   BioSyent intends to launch the product to the Canadian market in Q2 2021. “We